Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
about
Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosisRisk factors associated with adverse reactions to antituberculosis drugsComparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment.Recent advances in tuberculosis and nontuberculous mycobacteria lung disease.Assessing the risk of birth defects associated with exposure to fixed-dose combined antituberculous agents during pregnancy in rats
P2860
Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Acceptability, compliance, and ...... antituberculosis chemotherapy.
@en
Acceptability, compliance, and ...... antituberculosis chemotherapy.
@nl
type
label
Acceptability, compliance, and ...... antituberculosis chemotherapy.
@en
Acceptability, compliance, and ...... antituberculosis chemotherapy.
@nl
prefLabel
Acceptability, compliance, and ...... antituberculosis chemotherapy.
@en
Acceptability, compliance, and ...... antituberculosis chemotherapy.
@nl
P356
P1476
Acceptability, compliance, and ...... antituberculosis chemotherapy.
@en
P2093
Hong Kong Chest Service/British Medical Research Council
P304
P356
10.1164/AJRCCM/140.6.1618
P577
1989-12-01T00:00:00Z